NVIDIA Partners with Schrödinger to Further Accelerate Drug Discovery Worldwide
NVIDIA is partnering with Schrödinger to harness NVIDIA DGX A100 systems to further expand the speed and accuracy of Schrödinger’s computational drug discovery platform and enable rapid, accurate evaluation of billions of molecules for potential development of therapeutics.
About NVIDIA
NVIDIA‘s (NASDAQ: NVDA) invention of the GPU in 1999 sparked the growth of the PC gaming market and has redefined modern computer graphics, high performance computing and artificial intelligence. The company’s pioneering work in accelerated computing and AI is reshaping trillion-dollar industries, such as transportation, healthcare and manufacturing, and fueling the growth of many others. More information at https://nvidianews.nvidia.com/.
Certain statements in this press release including, but not limited to, statements as to: the benefits and impact of NVIDIA and Schrödinger partnering and what it will enable; the companies optimizing Schrödinger’s software platform; the benefits, impact and performance of our products and technologies; the companies advancing physics-based computing and machine learning for drug discovery; the work that goes into evaluating drug candidates; the collaboration enabling the pharmaceutical industry to accelerate drug discovery at scale and how they can use this technology; the availability of the Schrödinger platform; the benefits of predictive modeling built into the Schrödinger platform; Schrödinger’s software helping the biggest companies; how NVIDIA is contributing to Schrödinger’s work and advancing its suite of products; how customers can deploy Schrödinger software and what it allows; and how computational drug discovery is improving are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
© 2021 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, DGX A100, NVIDIA Clara and NVIDIA DGX SuperPOD are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated.